Speece Thorson Capital Group Inc buys $9,441,944 stake in Zimmer Biomet Holdings Inc (ZBH)

Zimmer Biomet Holdings Inc (ZBH) : Speece Thorson Capital Group Inc scooped up 1,063 additional shares in Zimmer Biomet Holdings Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 26, 2016. The investment management firm now holds a total of 76,964 shares of Zimmer Biomet Holdings Inc which is valued at $9,441,944.Zimmer Biomet Holdings Inc makes up approximately 2.03% of Speece Thorson Capital Group Inc’s portfolio.

Other Hedge Funds, Including , Boston Advisors reduced its stake in ZBH by selling 880 shares or 28.51% in the most recent quarter. The Hedge Fund company now holds 2,207 shares of ZBH which is valued at $270,755. Zimmer Biomet Holdings Inc makes up approx 0.01% of Boston Advisors’s portfolio.Cornerstone Advisors boosted its stake in ZBH in the latest quarter, The investment management firm added 57 additional shares and now holds a total of 2,073 shares of Zimmer Biomet Holdings Inc which is valued at $254,316. Zimmer Biomet Holdings Inc makes up approx 0.25% of Cornerstone Advisors’s portfolio. Simplex Trading sold out all of its stake in ZBH during the most recent quarter. The investment firm sold 10,837 shares of ZBH which is valued $1,370,772.First Manhattan Co reduced its stake in ZBH by selling 36,151 shares or 1.4% in the most recent quarter. The Hedge Fund company now holds 2,542,607 shares of ZBH which is valued at $317,368,206. Zimmer Biomet Holdings Inc makes up approx 1.90% of First Manhattan Co’s portfolio.Capstone Asset Management Co boosted its stake in ZBH in the latest quarter, The investment management firm added 1,448 additional shares and now holds a total of 20,325 shares of Zimmer Biomet Holdings Inc which is valued at $2,552,210. Zimmer Biomet Holdings Inc makes up approx 0.07% of Capstone Asset Management Co’s portfolio.

Zimmer Biomet Holdings Inc opened for trading at $127.47 and hit $131.33 on the upside on Friday, eventually ending the session at $131.14, with a gain of 2.88% or 3.67 points. The heightened volatility saw the trading volume jump to 19,58,481 shares. Company has a market cap of $26,128 M.

On the company’s financial health, Zimmer Biomet Holdings Inc reported $2.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.97. The company had revenue of $1934.00 million for the quarter, compared to analysts expectations of $1898.18 million. The company’s revenue was up 65.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.58 EPS.

Many Wall Street Analysts have commented on Zimmer Biomet Holdings Inc. Company shares were Reiterated by Needham on Jul 29, 2016 to “Buy”, Firm has raised the Price Target to $ 150 from a previous price target of $143 .Company shares were Reiterated by Needham on Jul 18, 2016 to “Buy”, Firm has raised the Price Target to $ 143 from a previous price target of $134 .Zimmer Biomet Holdings Inc was Initiated by Guggenheim to “Neutral” on Jun 9, 2016.

Zimmer Biomet Holdings Inc. formerly Zimmer Holdings Inc. is a musculoskeletal healthcare company. The Company designs manufactures and markets orthopedic reconstructive products; sports medicine biologics extremities and trauma products; spine bone healing craniomaxillofacial and thoracic products; dental implants and related surgical products. The Company manages its operations through three geographic segments: the Americas comprising principally of the United States and includes other North Central and South American markets; Europe comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers and directly to dental practices and dental laboratories.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *